Updated data from a Phase 3 clinical trial, ALEX, evaluating Roche’s (OTCQX:RHHBY) Alecensa (alectinib) versus Pfizer’s (NYSE:PFE)
Xalkori (crizotinib) in patients with anaplastic lymphoma kinase
(ALK)-positive non-small cell lung cancer (NSCLC) showed a higher
survival rate for Alecensa. The results were virtually presented at the
ASCO Scientific Program.
Specifically, the five-year survival rate in the alectinib arm was 62.5% compared to 45.5% in the crizotinib arm.
No new safety signals were observed.
ALK-positive NSCLC represents ~5% of NSCLC cases.
https://seekingalpha.com/news/3578574-roches-alecensa-increases-survival-in-certain-lung-cancer-patients
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.